Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort…
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with…
Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T…
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab SEOUL, South…
Winners received prestigious award in recognition of latest innovations in advancement in life sciences NEW YORK, Nov. 8, 2024 /PRNewswire/…
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Nov. 8, 2024 /PRNewswire/…
Sharp and Ricoh Top Award Winners HAMBURG, N.J., Nov. 8, 2024 /PRNewswire/ -- The Cannata Report, the leading office technology news…
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have been awarded The Galien Foundation 2024 Prix…
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and…
STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- THIRD QUARTER (JULY - SEPTEMBER 2024) Order intake SEK 253.4 M (240.7)Net sales SEK…